Piramal Pharma gets ESG Rating of 68.5 from SES ESG for FY25
Piramal Pharma Limited received an ESG Rating of 68.5 for FY 2024-25 from SES ESG Research. The rating was assigned voluntarily by SES ESG based on publicly available data. The company has published this information on its website.
The announcement is a routine disclosure regarding an ESG rating. It does not involve significant financial transactions, strategic shifts, or regulatory actions that would materially impact the company's operations or stock price in the short term. The rating was assigned voluntarily and not as part of a company-initiated process.
The announcement is a factual disclosure of an ESG rating assigned by a third-party agency. While an ESG rating can be seen positively, the company clarifies it did not engage the agency, making the sentiment neutral as it's a voluntary assessment.
Piramal Pharma Limited (PPL) announced on March 20, 2026, that SES ESG Research Pvt. Ltd. has assigned an Environment, Social, and Governance (ESG) Rating of 68.5 to the company for the Financial Year 2024-25. This rating is based on data made publicly available by the company for that year.
The company clarified that it had not engaged SES ESG for this rating; SES ESG voluntarily prepared the report by considering the ESG factors reported by Piramal Pharma.
The rating and its publication details are available on the SES ESG website, and the company has also uploaded this intimation on its own website at https://www.piramalpharma.com/.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.